ImpediMed Limited
ASX:IPD Rapport sur les actions
Capitalisation boursière : AU$111.3m
ImpediMed Bilan de santé
Santé financière contrôle des critères 6/6 ImpediMed possède un total de capitaux propres de A$40.7M et une dette totale de A$0.0, ce qui porte son ratio d'endettement à 0%. Son actif total et son passif total sont A$47.0M et de A$6.2M.
Informations clés Ratio de couverture des intérêts n/a Argent liquide AU$24.63m Fonds propres AU$40.74m Total du passif AU$6.24m Total des actifs AU$46.99m
Mises à jour récentes de la santé financière
Afficher toutes les mises à jour
ImpediMed Limited to Report Q1, 2025 Results on Oct 22, 2024 Oct 15
ImpediMed Limited, Annual General Meeting, Nov 19, 2024 Sep 27
Price target decreased by 8.8% to AU$0.15 Sep 09
Consensus revenue estimates decrease by 14% Sep 04
Board Member recently bought AU$73k worth of stock Sep 03
Full year 2024 earnings: EPS exceeds analyst expectations while revenues lag behind Aug 30
Forecast to breakeven in 2027 Aug 29
ImpediMed Limited to Report Fiscal Year 2024 Results on Aug 29, 2024 Aug 23
Forecast to breakeven in 2026 Jul 30 ImpediMed Limited Appoints Parmjot Bains as CEO on an ongoing basis
We Think ImpediMed (ASX:IPD) Can Afford To Drive Business Growth Jun 26
ImpediMed Limited Appoints Fiona Bones as A Non-Executive Director Jun 08
New minor risk - Market cap size Jun 04
Independent Non-Executive Director recently bought AU$50k worth of stock May 15
ImpediMed Limited to Report Q3, 2024 Results on Apr 30, 2024 Apr 20
Price target decreased by 9.6% to AU$0.18 Apr 16
ImpediMed to Present Chronic Breast Cancer-Related Lymphedema Study Results at American Society of Breast Surgeons Annual Meeting Apr 11
Independent Non-Executive Director recently bought AU$100k worth of stock Mar 28
ImpediMed (ASX:IPD) Is In A Good Position To Deliver On Growth Plans Mar 05
Consensus revenue estimates decrease by 13% Mar 04
Independent Non-Executive Director recently bought AU$90k worth of stock Mar 02
Price target decreased by 12% to AU$0.19 Feb 03
No longer forecast to breakeven Feb 03
High number of new and inexperienced directors Feb 01
New minor risk - Share price stability Jan 31
ImpediMed Limited to Report First Half, 2024 Results on Feb 27, 2024 Jan 23
Independent Non-Executive Director recently bought AU$135k worth of stock Dec 19
Companies Like ImpediMed (ASX:IPD) Are In A Position To Invest In Growth Nov 23
Consensus revenue estimates decrease by 20% Nov 21 ImpediMed Limited Announces CFO Changes
Price target decreased by 16% to AU$0.23 Nov 10
Price target increased by 21% to AU$0.27 Nov 01
ImpediMed Limited to Report Q1, 2024 Results on Oct 31, 2023 Oct 24
ImpediMed Limited, Annual General Meeting, Nov 30, 2023 Oct 12
High number of new directors Oct 05
ImpediMed Limited Announce the Appointment of Steven Chen as Chief Medical Officer Sep 27
Consensus revenue estimates decrease by 23% Sep 06
Full year 2023 earnings: EPS and revenues miss analyst expectations Aug 31
Full year 2023 earnings: EPS and revenues miss analyst expectations Aug 31
ImpediMed Limited, Annual General Meeting, Sep 28, 2023 Aug 18
Price target increased by 27% to AU$0.21 Jul 21
ImpediMed Limited to Report Q4, 2023 Results on Jul 24, 2023 Jul 17
Is ImpediMed (ASX:IPD) In A Good Position To Deliver On Growth Plans? Jul 11
ImpediMed Limited Appoints Daniel Sharp as Director Jul 06
Executive Director recently bought AU$144k worth of stock Jun 28
Independent Non-Executive Chairman recently bought AU$82k worth of stock Jun 14
No longer forecast to breakeven May 30
MD, CEO & Director recently bought AU$52k worth of stock Apr 22
MD, CEO & Director recently bought AU$54k worth of stock Mar 31
Price target increased by 25% to AU$0.18 Mar 29
We Think ImpediMed (ASX:IPD) Needs To Drive Business Growth Carefully Mar 27
MD, CEO & Director recently bought AU$64k worth of stock Mar 08
First half 2023 earnings released: AU$0.01 loss per share (vs AU$0.006 loss in 1H 2022) Feb 25
Price target decreased by 7.7% to AU$0.17 Jan 31
ImpediMed Limited to Report Q2, 2023 Results on Jan 30, 2023 Jan 24
ImpediMed Limited Presents New Data at 2022 San Antonio Breast Cancer Symposium Shows Early Detection Using L-Dex and Intervention Improves Lymphedema Progression-Free Survival Dec 16 Impedimed Limited Announces CEO Changes
ImpediMed Limited Announces Management Changes Nov 22
Less than half of directors are independent Nov 16
Executive Director & Interim CEO recently bought AU$164k worth of stock Nov 01
Less than half of directors are independent Oct 28
ImpediMed Limited Announces Current Data Support Early Detection and Intervention to Reduce Rates of Breast Cancer Related Lymphedema Oct 27
ImpediMed Limited to Report Q1, 2023 Results on Oct 19, 2022 Oct 13
ImpediMed Expands Use of SOZO in Leading Cancer Centers Focused on Reducing the Impact of Lymphedema after Breast Cancer Oct 12
ImpediMed Announces U.S. Launch of Lymphedema Prevention Program with GenesisCare a Global Organization Dedicated to Care of Cancer Patients Oct 05
Here's Why We're Not Too Worried About ImpediMed's (ASX:IPD) Cash Burn Situation Sep 28
Consensus forecasts updated Sep 04
Price target decreased to AU$0.18 Aug 31
ImpediMed Limited Announces Board Changes Aug 30
Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind Aug 30
ImpediMed Limited, Annual General Meeting, Oct 26, 2022 Aug 29
Price target decreased to AU$0.22 Aug 03
ImpediMed Limited Announces Executive Changes Jul 27
Less than half of directors are independent Jul 27 ImpediMed Limited Announces Resignation of Richard Carreon as Managing Director
We're Not Worried About ImpediMed's (ASX:IPD) Cash Burn Jun 10
ImpediMed Limited Announces Release of the New Version 4.1 Software for the SOZO Digital Health Platform Jun 02
No longer forecast to breakeven Apr 27
ImpediMed Limited to Report Q3, 2022 Results on Apr 28, 2022 Apr 22
New Bone Data Showing Strong Correlation Between ImpediMed's SOZO and DXA in Cancer Patients Presented At 39Th Annual Miami Breast Cancer Conference Mar 07
No longer forecast to breakeven Mar 04
Consensus revenue estimates fall by 21% Mar 03
First half 2022 earnings: EPS exceeds analyst expectations while revenues lag behind Feb 28
Now 24% undervalued Feb 22
Now 21% undervalued Feb 03
A Look At The Fair Value Of ImpediMed Limited (ASX:IPD) Feb 01
Price target increased to AU$0.32 Nov 04
Forecast to breakeven in 2024 Nov 02
Price target increased to AU$0.25 Oct 20
FDA Grants Breakthrough Device Designation for ImpediMed's SOZO Digital Health Platform for Renal Failure Aug 31
Analyse de la situation financière
Passif à court terme: Les actifs à court terme de IPD ( A$29.5M ) dépassent ses passifs à court terme ( A$4.7M ).
Passif à long terme: Les actifs à court terme de IPD ( A$29.5M ) dépassent ses passifs à long terme ( A$1.6M ).
Historique et analyse du ratio d'endettement
Niveau d'endettement: IPD est sans dette.
Réduire la dette: IPD n'a eu aucune dette au cours des 5 dernières années.
Analyse des pistes de trésorerie Pour les entreprises qui ont été en moyenne déficitaires dans le passé, nous évaluons si elles disposent d'au moins un an de trésorerie.
Piste de trésorerie stable: IPD dispose d'une piste de trésorerie suffisante pour plus d'un an sur la base de son flux de trésorerie disponible actuel.
Prévisions de trésorerie: IPD dispose d'une marge de trésorerie suffisante pour 1.4 ans si le flux de trésorerie disponible continue de croître à un taux historique de 1.3 % chaque année.
Découvrir des entreprises saines Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"display-ssr-flag","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}
